SINO BIOPHARM Shares Rise Nearly 4% by Midday, Bank of America Securities Reiterates "Buy" Rating

Deep News01-13

SINO BIOPHARM (01177) saw its intraday gain exceed 4%. As of the time of writing, the stock price was up 3.50%, trading at HK$7.09, with a turnover of HK$439 million.

Recently, Bank of America Securities released a report indicating that mainland China's pharmaceutical industry drug sales in October fell 3% year-on-year, a significant slowdown compared to the growth rate in September. The firm reiterated its "Buy" rating on SINO BIOPHARM.

The report showed that hospital channel sales turned to a year-on-year decline of 3.3%, while retail channel sales remained largely flat. The performance of SINO BIOPHARM's products was mixed, with sales growth for some core products but significant declines for others.

Based on the sales data, Bank of America Securities made minor adjustments to its revenue forecasts for 2026 and 2027, lowering the target price from HK$9.4 to HK$8.3. Furthermore, CSPC Pharmaceutical Group maintained its "Underperform" rating due to sluggish sales of its key drugs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118861703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118861703","market":"sg","top_or_hot":-1,"title":"SINO BIOPHARM Shares Rise Nearly 4% by Midday, Bank of America Securities Reiterates \"Buy\" Rating","media":"Deep News","content":"<p>SINO BIOPHARM (01177) saw its intraday gain exceed 4%. As of the time of writing, the stock price was up 3.50%, trading at HK$7.09, with a turnover of HK$439 million.</p>\n<p>Recently, Bank of America Securities released a report indicating that mainland China's pharmaceutical industry drug sales in October fell 3% year-on-year, a significant slowdown compared to the growth rate in September. The firm reiterated its \"Buy\" rating on SINO BIOPHARM.</p>\n<p>The report showed that hospital channel sales turned to a year-on-year decline of 3.3%, while retail channel sales remained largely flat. The performance of SINO BIOPHARM's products was mixed, with sales growth for some core products but significant declines for others.</p>\n<p>Based on the sales data, Bank of America Securities made minor adjustments to its revenue forecasts for 2026 and 2027, lowering the target price from HK$9.4 to HK$8.3. Furthermore, CSPC Pharmaceutical Group maintained its \"Underperform\" rating due to sluggish sales of its key drugs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINO BIOPHARM Shares Rise Nearly 4% by Midday, Bank of America Securities Reiterates \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINO BIOPHARM Shares Rise Nearly 4% by Midday, Bank of America Securities Reiterates \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-13 11:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SINO BIOPHARM (01177) saw its intraday gain exceed 4%. As of the time of writing, the stock price was up 3.50%, trading at HK$7.09, with a turnover of HK$439 million.</p>\n<p>Recently, Bank of America Securities released a report indicating that mainland China's pharmaceutical industry drug sales in October fell 3% year-on-year, a significant slowdown compared to the growth rate in September. The firm reiterated its \"Buy\" rating on SINO BIOPHARM.</p>\n<p>The report showed that hospital channel sales turned to a year-on-year decline of 3.3%, while retail channel sales remained largely flat. The performance of SINO BIOPHARM's products was mixed, with sales growth for some core products but significant declines for others.</p>\n<p>Based on the sales data, Bank of America Securities made minor adjustments to its revenue forecasts for 2026 and 2027, lowering the target price from HK$9.4 to HK$8.3. Furthermore, CSPC Pharmaceutical Group maintained its \"Underperform\" rating due to sluggish sales of its key drugs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"","article_id":"1118861703","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118861703","pubTimestamp":1768275189,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"SINO BIOPHARM (01177) saw its intraday gain exceed 4%. As of the time of writing, the stock price was up 3.50%, trading at HK$7.09, with a turnover of HK$439 million. Recently, Bank of America...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1515":"抗疫概念","BK1191":"制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"中国生物制药股价午盘涨近4%美银证券重申“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"01177":1},"content_text":"SINO BIOPHARM (01177) saw its intraday gain exceed 4%. As of the time of writing, the stock price was up 3.50%, trading at HK$7.09, with a turnover of HK$439 million.\nRecently, Bank of America Securities released a report indicating that mainland China's pharmaceutical industry drug sales in October fell 3% year-on-year, a significant slowdown compared to the growth rate in September. The firm reiterated its \"Buy\" rating on SINO BIOPHARM.\nThe report showed that hospital channel sales turned to a year-on-year decline of 3.3%, while retail channel sales remained largely flat. The performance of SINO BIOPHARM's products was mixed, with sales growth for some core products but significant declines for others.\nBased on the sales data, Bank of America Securities made minor adjustments to its revenue forecasts for 2026 and 2027, lowering the target price from HK$9.4 to HK$8.3. Furthermore, CSPC Pharmaceutical Group maintained its \"Underperform\" rating due to sluggish sales of its key drugs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118861703","isCrawlerRequest":true}